Oxy-inflammation in hyperbaric oxygen therapy applications
Accepted: 27 July 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Hyperbaric oxygen therapy (HBOT) is a non-invasive method of O2 delivery that induces systemic hyperoxia. Hyperbaric chamber consists of a pressure vessel and a compressed breathing gas supply, which can regulate internal pressure. The chamber delivers 100% O2 to patients according to predetermined protocols and is monitored by trained personnel. HBOT relies on increasing the inspired O2 fraction (fiO2) and elevating the partial pressure of O2 (pO2). O2 is typically administered at pressures between 1.5 and 3.0 ATA for 60 to 120 minutes, depending on the clinical presentation. Currently, there are 15 indications for HBOT approved by the Undersea and Hyperbaric Medicine Society, categorized into three groups: emergency medicine, wound healing acceleration, and antimicrobial effects. The present narrative review aims to elucidate the mechanisms action underlying HBOT, particularly oxy-inflammation, in various pathologies within these categories.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.